Trials / Recruiting
RecruitingNCT05801237
PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor
A Phase Ib/II Clinical Trial to Evaluate the Tolerability, Safety, Pharmacokinetics and Preliminary Antitumor Activity of PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- Sponsor
- Shanghai HyaMab Biotech Co.,Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase I Clinical Trial to Evaluate the Tolerability, Safety, Pharmacokinetics and Preliminary Antitumor Activity of PE0116 and PE0105 Injection in Treatment of Patients with Advanced Solid Tumor.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PE0116&PE0105 | This is a Phase I Clinical Trial to Evaluate the Tolerability, Safety, Pharmacokinetics and Preliminary Antitumor Activity of PE0116 and PE0105 Injection in Treatment of Patients with Advanced Solid Tumor |
Timeline
- Start date
- 2023-09-21
- Primary completion
- 2026-09-01
- Completion
- 2026-12-01
- First posted
- 2023-04-06
- Last updated
- 2023-12-15
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05801237. Inclusion in this directory is not an endorsement.